

REMARKS

Claims 1-7 are pending in this application. By this Amendment, claims 1 and 2 are amended for better clarity, and new claim 7 is added. The specification is amended based on the disclosure of Fig. 2.

Applicants thank Examiner Cruz for the courtesy extended to Applicants' representative, Mr. Luo, during the March 22, 2005 personal interview. The substance of the personal interview is incorporated in the following remarks.

The Examiner is respectfully requested to consider the references submitted with the February 7, 2005 Information Disclosure Statement and the Information Disclosure Statement concurrently filed herewith. A copy of the February 7, 2005 Form PTO-1449 is enclosed herein for the Examiner's convenience.

The Office Action provisionally rejects claims 1, 3 and 6 under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1, 8 and 9 of co-pending Application No. 10/645,775. Applicants will consider filing a Terminal Disclaimer to overcome this rejection when this application is allowed.

The Office Action objects to claims 1-6. Claims 1 and 2 are amended. As discussed during the personal interview, the amendments made to claims 1 and 2 better clarify the subject matter recited therein, and overcome the objection to claims 1-6. Accordingly, withdrawal of the objection to claims 1-6 is respectfully requested.

The Office Action rejects claims 1, 2 and 4-6 under 35 U.S.C. §102(b) over U.S. Patent 6,335,828 to Hashimoto et al.; and claim 3 under 35 U.S.C. §103(a) over Hashimoto in view of U.S. Patent Application Publication 2004/0070845 to Karasawa et al. These rejections are respectfully traversed.

As discussed during the personal interview, Hashimoto does not disclose or suggest microlenses that are arrayed in a first direction and a second direction, with adjacent

microlenses having common sides, the first direction being rotated by 45 degrees with respect to the horizontal direction, the second direction being perpendicular to the first direction, as recited in claim 1. In addition, Applicants respectfully submit that Karasawa does not supply the subject matter lacking in Hashimoto. Thus, as agreed to during the personal interview, claim 1 is patentable over the prior art of record.

Additionally, Applicants respectfully submit that dependent claims 2-6 are each patentable at least in view of the patentability of claim 1, from which they depend, as well as for the additional features they recite.


For at least the above reasons, withdrawal of the rejection of claims 1-6 under 35 U.S.C. §102(b) and 35 U.S.C. §103(a) is respectfully requested.

The subject matter recited in new claim 7 is disclosed in the originally filed Fig. 2, as well as in the amended specification. Claim 7 is patentable at least in view of the patentability of claim 1, from which it depends, as well as for the additional feature it recites.

In view of the foregoing, it is respectfully submitted that this application is in condition for allowance. Favorable reconsideration and prompt allowance of claims 1-7 are earnestly solicited.

Should the Examiner believe that anything further would be desirable in order to place this application in even better condition for allowance, the Examiner is invited to contact the undersigned at the telephone number set forth below.

Respectfully submitted,


James A. Oliff
Registration No. 27,075

Gang Luo
Registration No. 50,559

JAO:GXL/djb

Attachments:

Copy of 2/7/2005 Form PTO-1449
Information Disclosure Statement concurrently filed herewith

Date: April 22, 2005

OLIFF & BERRIDGE, PLC
P.O. Box 19928
Alexandria, Virginia 22320
Telephone: (703) 836-6400

<p>DEPOSIT ACCOUNT USE AUTHORIZATION Please grant any extension necessary for entry; Charge any fee due to our Deposit Account No. 15-0461</p>
